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AbstrACt
Objectives Guidelines for the use of drugs for type 2 
diabetes mellitus (T2DM) have changed since 2000, and 
new classes of drug have been introduced. Our aim was 
to describe how drug choice at initiation and first stage of 
intensification have changed over this period, and to what 
extent prescribing was in accord with clinical guidelines, 
including adherence to recommendations regarding kidney 
function.
Design Repeated cross-sectional study.
setting UK electronic primary care health records from 
the Clinical Practice Research Datalink.
Participants Adults initiating treatment with a drug for 
T2DM between January 2000 and July 2017.
Primary and secondary outcome measures The 
primary outcomes were the proportion of each class 
of T2DM drug prescribed for initiation and first-stage 
intensification in each year. We also examined drug 
prescribing by kidney function and country within the UK.
results Of 280 241 people initiating treatment with 
T2DM drugs from 2000 to 2017, 73% (204 238/280 241) 
initiated metformin, 15% (42 288/280 241) a sulfonylurea, 
5% (12 956/280 241) with metformin and sulfonylurea 
dual therapy and 7% (20 759/280 241) started other 
options. Clinicians have increasingly prescribed metformin 
at initiation: by 2017 this was 89% (2475/2778) of drug 
initiations. Among people with an estimated glomerular 
filtration rate of ≤30 mL/min/1.73 m2, the most common 
drug at initiation was a sulfonylurea, 58% (659/1135). In 
2000, sulfonylureas were the predominant drug at the 
first stage of drug intensification (87%, 534/615) but by 
2017 this fell to 30% (355/1183) as the use of newer 
drug classes increased. In 2017, new prescriptions for 
dipeptidyl peptidase-4 inhibitors (DPP4i) and sodium/
glucose cotransporter-2 inhibitors (SGLT2i) accounted for 
42% (502/1183) and 22% (256/1183) of intensification 
drugs, respectively. Uptake of new classes differs by 
country with DPP4is and SGLT2is prescribed more in 
Northern Ireland and Wales than England or Scotland.
Conclusions Our findings show markedly changing 
prescribing patterns for T2DM between 2000 and 2017, 
largely consistent with clinical guidelines.
IntrODuCtIOn 
In the UK, the vast majority of prescribing for 
type 2 diabetes mellitus (T2DM) is undertaken 
within primary care. The aim of treatment is 
to reduce hyperglycaemia and morbidities 
associated with T2DM, such as cardiovascular 
disease and microvascular complications 
such as chronic kidney disease (CKD) or 
retinopathy.1 2 National Institute for Health 
and Care Excellence (NICE) and Scottish 
Intercollegiate Guidelines Network (SIGN) 
provide clinical guidance for the manage-
ment of T2DM. After lifestyle changes, both 
NICE (NG28) and SIGN (154) recommend 
a series of intensification steps, adding drugs 
to a baseline of metformin monotherapy and 
only stopping metformin if there are clinical 
reasons to do so.1 2 Estimates suggest that 
30%–50% of people who started treatment 
on metformin monotherapy in the USA and 
Europe went on to further drug intensifica-
tion.3 4 
There are an increasing number of poten-
tial drug classes for the first stage of intensi-
fication after metformin monotherapy. Two 
new drug classes have recently been intro-
duced: dipeptidyl peptidase-4 inhibitors 
(DPP4is; first licensed in the UK in 2007) and 
sodium-glucose cotransporter-2 inhibitors 
(SGLT2is first licensed in the UK in 2012). 
Guidelines have been updated to reflect these 
new options (figure 1).1 2 5 6 Sulfonylureas 
(SU), SGLT2is, DPP4is and thiazolidinedi-
ones (TZD) are the current drug options 
for the first stage of drug intensification and 
are associated with different risk profiles and 
possibly specific benefits.7 8 In light of the 
changing treatment guidelines, we aimed 
strengths and limitations of this study
 ► This study uses contemporary UK primary care 
data to examine how prescribing at the first stage 
of treatment intensification for type 2 diabetes after 
metformin monotherapy has changed from 2000 to 
2017.
 ► Using long-term prescribing data has enabled us to 
compare people at the same stage of treatment.
 ► We may have included some patients with type 1 
diabetes, and may have wrongly classified some 
people who were changing rather than intensifying 
treatment.
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to describe patterns of prescribing using UK primary 
care data between 2000 and 2017, examining trends in 
prescribing at treatment initiation and at the point of 
first drug intensification, and to investigate the degree of 
concordance with guideline recommendations, in partic-
ular in relation to kidney function. In secondary analyses, 
we have explored whether there is variation in local prac-
tice by describing prescribing according to geographic 
location and clusters of general practices.
MethODs
study setting
This observational study used data from the UK Clinical 
Practice Research Datalink (CPRD), a source of pseud-
onymised primary care health data which is regularly 
audited to ensure quality. CPRD data include demo-
graphic and lifestyle factors, records of prescriptions, 
clinical and test records and referrals to secondary care. 
The data come from primary care providers in England, 
Wales, Scotland and Northern Ireland and have been 
used extensively for clinical and pharmacoepidemiology 
studies, with previous validation studies suggesting that 
diagnoses coded in CPRD are highly reproducible from 
other data sources.9 10
Participants
We identified all individuals aged ≥18 years who started 
drug treatment for T2DM between 2000 and 2017. 
Although the onset of T2DM is typically over the age of 
40 years, the age of diagnosis is decreasing over time, and 
earlier onset (and longer duration) is associated with 
poorer patient outcomes. We therefore only excluded the 
very young who are substantially more likely to have type 
1 diabetes mellitus (T1DM).11 We specified that patients 
should be registered at a general practitioner (GP) 
practice recording research quality data for a period of 
12 months before starting drug treatment for diabetes to 
restrict the cohort to only new users of T2DM drugs.
We excluded women with a record of pregnancy (within 
12 months either side of baseline prescription) as UK 
prescribing guidelines recommend different drug regi-
mens for pregnant and breastfeeding women compared 
with other patients with T2DM.12 13
Codes to identify T2DM drugs were created based on 
British National Formulary T2DM chapters and drug 
codes are provided in the online supplementary file and 
on LSHTM compass, http:// datacompass. lshtm. ac. uk/ 
649/. We used the CPRD data released in July 2017.
Definition of exposure, outcome and covariates
Drug initiation cohort
We described prescribing for two cohorts of patients. The 
first included individuals who received any prescriptions 
for their first antidiabetic drug. We identified the first 
T2DM drug prescribed in their patient record. Where 
more than one drug was prescribed on the day of initi-
ation, the treatment was recorded as a combination 
therapy of the drugs prescribed.
First stage of drug intensification cohort
Metformin is the only drug recommended by NICE and 
SIGN for drug initiation, with further drugs subsequently 
added if greater glycaemic control is required at the first 
stage of intensification. Therefore, we went on to describe 
prescribing among patients who intensify treatment after 
a period of metformin monotherapy. We described the 
first new drug prescribed after metformin monotherapy 
without any time limit. We sought to do this and exclude 
those who switched treatment by requiring that included 
individuals had a further prescription for metformin 
within 60 days of the prescription for a new drug class. 
Figure 1 Changing National Institute for Health and Care Excellence (NICE) recommendations for type 2 diabetes mellitus 
(T2DM) drug treatment. CG, clinical guideline; DPP4i, dipeptidyl peptidase-4 inhibitor; GLP1, glucagon-like peptide-1; 
Ins, insulin; MTF, metformin; NG, NICE guideline; Pio, pioglitazone; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SU, 
sulfonylurea; TZD, thiazolidinedione.1 2 5 6 14 21 33 34
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We did not describe further prescribing for patients who 
switch treatment from metformin as our focus is on treat-
ment intensification rather than switching.
Covariates
For both cohorts we investigated how prescribing has 
changed over time by describing patterns for each 
calendar year, with year based on the day that the initi-
ation or first intensification drug was first recorded 
in the patient record. Metformin is contraindicated 
for those with an increased risk of lactic acidosis such 
as those with reduced kidney function. Therefore, 
we also described treatment patterns for people with 
reduced renal function: (1) in individuals whose most 
recent estimated glomerular filtration rate (eGFR) 
was ≤30 mL/min/1.73 m2 prior to drug prescription to 
reflect current treatment guidance, and (2) individuals 
with a serum creatinine higher than 130 µmol/L prior 
to drug prescription, to reflect guidance from 2002 that 
used this higher serum creatinine target.14 15 eGFR was 
calculated using the last creatinine result, recorded 
not more than 540 days (18 months) prior to the date 
of treatment prescription, since we expected creatinine 
to be measured annually as recommended during the 
study period by Quality Outcomes Framework16 and the 
National Diabetes Audit.17 We calculated eGFR using the 
CKD-EPI equation18 excluding the ethnicity factor as this 
is not entered in CPRD for a substantial proportion of 
individuals.19
To assess country-level differences, we stratified 
prescribing according to the location of each general 
practice: England, Northern Ireland, Scotland and Wales. 
We also described first stage of intensification prescribing 
according to Clinical Commissioning Group (CCG) 
groupings. CCGs are groups of GP practices that are 
responsible for commissioning local health services for 
patients, and may have shared management protocols or 
prescribing guidance. Here, GP practices are identified 
to be in the same CCG but there is no other identifiable 
information on the location of the CCG.
statistical analysis
To examine how drug prescribing changed over time we 
first described patterns using counts of drug initiations 
between 2000 and 2017 with total prescribing for each 
year as the denominator. Then, we repeated this for the 
first stage of intensification prescribing patterns. We 
described initiation prescribing in the subgroup of indi-
viduals with reduced renal function, and we provided 
prescribing patterns for the first stage of intensification 
according to country and CCG. We calculated 95% CIs 
for the proportions using the standard normal distribu-
tion approximation. For people intensifying treatment 
in 2016, we calculated the mean time between starting 
metformin and the second treatment, we restricted to 
2016 as this was the final year with complete data, and 
restricting to a single year reduced differential lead time 
due to non-availability of newer drugs in previous years.
Data extraction and processing of CPRD data was 
completed in Stata MP (V.14). All data analyses were 
completed using R and R packages for reproducible 
research. We reported our findings according to the 
RECORD reporting guidelines.20
ethical and scientific approval
The research protocol was approved by the Independent 
Scientific Advisory Committee (ISAC) for MHRA Data-
base Research (protocol number 16_267). The protocol 
was made available to reviewers for peer review. Ethical 
approval for observational research using CPRD GOLD 
with approval from ISAC has been granted by a Health 
Research Authority Research Ethics Committee (East 
Midlands-Derby, REC reference number 05/MRE04/87). 
This study was also approved by the London School of 
Hygiene and Tropical Medicine Ethics Committee (refer-
ence 11923).
Patient and public involvement statement
Patients were not involved in the design or conduct of 
the study. We plan to disseminate the results through 
peer review publication.
results
We identified 280 241 people initiating treatment with 
an antidiabetic drug between the start of 2000 and July 
2017. Inclusions and exclusions are shown in figure 2. 
Of those initiating treatment, 204 238/280 241 (73%) 
initiated with metformin monotherapy, 42 288/280 241 
(15%) with SU monotherapy and 12 956/280 241 (5%) 
with metformin and SU dual therapy. Insulin mono-
therapy represents 6771/280 241 (2%) of initiations for 
Figure 2 Flow diagram showing the creation of the cohorts 
and reasons for exclusion. CPRD, Clinical Practice Research 
Datalink; T2DM, type 2 diabetes mellitus. 
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the period and 13 988/280 241 (5%) started another 
drug option. Of this 5%, the most common drugs were 
insulin in combination with metformin (2850/13 988), 
TZD in combination with metformin (1405/13 988) or 
TZD alone (1393/13 988). A full list of combinations is 
provided in online supplementary table 1.
temporal patterns of prescribing: treatment initiation
Patterns of treatment initiation drug prescribing changed 
over time (figure 3 and online supplementary table 2). In 
2000, GPs prescribed SU monotherapy more often than 
metformin monotherapy but have increasingly prescribed 
metformin which now accounts for 89% (95% CI 88% to 
90%) of drug initiations for T2DM. A small number of 
people in our drug initiation cohort start treatment on 
insulin therapy and this declines over time. Prescribing of 
insulin fell from 4% in 2000 to 0.58% in 2017.
Prescribing among people with reduced renal function
We found 145 822/280 241 (52%) people with eGFR 
measured in the 540 days prior to initiating drug therapy. 
Of these 1135/145 822 (1%) had an eGFR ≤30 mL/
min/1.73 m2 and 5395/145 822 (4%) had a serum creati-
nine ≥130 µmol/L. Among people with an eGFR ≤30 mL/
min/1.73 m2 the most common drug for initiating treat-
ment was an SU at 58% (659/1135) of total prescribing 
from 2000 to 2016. Prescribing of metformin as the first 
drug in this group fell steadily from 29% (95% CI 28% to 
30%) in 2000 to 9.5% (95% CI 9% to 10%) in 2016. Since 
being licensed in 2007, prescriptions for DPP4is as initial 
therapy for this subgroup have steadily increased to 33% 
(95% CI 32% to 34%) in 2016. Full details of prescribing 
are supplied in online supplementary table 3. A compar-
ison of initiation drug prescribing between the current 
and earlier guidance on renal function is presented 
in online supplementary figure 1.
temporal patterns of prescribing: first stage of drug 
intensification
Of the individuals who started metformin monotherapy, 
we identified 105 348/277 232 (38%) people who started 
on metformin and then received a second class of T2DM 
drug. Of these, 79 941/105 348 (76%) were prescribed 
metformin in the 60 days after the new drug prescription, 
indicating treatment intensification rather than switching. 
Among these 79 941 people, the drugs prescribed at the 
first stage of drug intensification have changed over the 
period of the study (figure 4).
In 2000, SU prescribing dominated drug choices at the 
first stage of intensification, accounting for 87% (95% CI 
84% to 90%) of new drug intensifications. By 2017, this fell 
to 30% (95% CI 25% to 35%). Between 2000 and 2006, 
there was a rise in the use of TZD class prescribing, but after 
Figure 3 Drug prescribing at T2DM drug initiation 2000–2017.14 21 22 CG, clinical guideline; CKD, chronic kidney disease; 
eGFR, estimated glomerular filtration rate; QOF, Quality Outcomes Framework; SU, sulfonylurea; T2DM, type 2 diabetes 
mellitus.
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2006, TZD use fell. In 2017, TZD prescribing accounted for 
only 2% (95% CI 0% to 8%) of prescribing, compared with 
a peak of 45% (95% CI 43% to 47%) in 2006. Prescribing 
of two new drug classes, DPP4is and SGLT2is increased 
since their introduction in 2007 and 2012, respectively. 
In 2017, new prescriptions for DPP4is accounted for 42% 
(95% CI 38% to 47%) of first stage of intensification drug 
choices. SGLT2i prescribing is rising, accounting for 22% 
(95% CI 17% to 27%) of new drug intensifications in 2017 
(online supplementary table 4). Other than insulin (about 
21 months) the other drugs were all started after a similar 
time period following metformin monotherapy (around 
3–3.7 years) (online supplementary table 5).
regIOnAl DIfferenCes
Prescribing practice differs between countries within the UK 
(figure 5, online supplementary table 6). For 2013–2017, 
GPs in Wales and Northern Ireland prescribed DPP4is in 
45% (95% CI 42% to 48%) and 46% (95% CI 41% to 51%) 
of intensifications whereas in Scotland and England GPs 
prescribed DPP4is in just 30% (95% CI 26% to 34%) and 
Figure 4 First-stage intensification prescribing as a percentage of total prescribing 2000–2017.31 35 36 DPP4i, dipeptidyl 
peptidase-4 inhibitor; EU, European Union; GLP1, glucagon-like peptide-1; MI, myocardial infarction; SGLT2i, sodium/glucose 
cotransporter-2 inhibitor; SU, sulfonylurea; TZD, thiazolidinediones.
Figure 5 Proportions of patients at first-stage intensification prescribed a DPP4i, SU, SGLT2i and other drugs, by country, 
2013–2017. DPP4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium/glucose cotransporter-2 inhibitor; SU, sulfonylurea.
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36% (95% CI 34% to 38%) of patients intensifying treat-
ment. GPs in Northern Ireland prescribed SGLT2is in 18% 
(95% CI 11% to 24%) of intensifications compared with 
13% (95% CI 9% to 16%) in Wales, 12% (95% CI 8% to 
16%) in Scotland and 9% (95% CI 7% to 11%) in England. 
We also found marked heterogeneity of prescribing practice 
across CCG groupings (online supplementary figure 2).
DIsCussIOn
Our results show that prescribing of metformin has increased 
and prescribing of SUs has fallen at drug initiation for T2DM 
between 2000 and 2017, and shows increasing accordance 
with recommendations from national and international 
guidelines. In patients with an eGFR ≤30 mL/min/1.73 m2 
the most commonly prescribed initiation drug class was 
SUs until 2015, but since then DPP4is are more commonly 
prescribed. Of note, we found that approximately 1 in 10 
people are prescribed metformin despite an eGFR ≤30 mL/
min/1.73 m2. Prescribing patterns at the first stage of drug 
therapy intensification have also changed, with prescribing 
of SUs and TZDs falling, while that of newer drug classes 
has risen. By 2017, the most commonly prescribed addi-
tion to metformin was a DPP4i. Prescribing practice differs 
by country within the UK. We identified large differences 
in prescribing practice between countries in the UK, with 
Northern Ireland and Wales prescribing both DPP4is and 
SGLT2is more commonly than in England or Scotland. We 
also show large variations in prescribing practice between 
CCGs.
Our large study uses data from a source of population 
representative primary care records from across the UK 
to provide great insight into real-world clinical practice 
from 2000 to 2017. We have attempted to improve direct 
comparability by developing cohorts that reflect distinct 
stages of the management of patients with T2DM, rather 
than examining total prescribing. We have been able to 
characterise renal function prior to drug initiation for 
the majority of patients to explore changing concordance 
with prescribing recommendations.
However, there are limitations to this analysis. We do 
not know if the prescribing was initiated in primary or 
secondary care. In the absence of wider demographic 
features about the CCGs such as age, socioeconomic status 
or ethnicity distributions we cannot explore factors that 
might drive variation in prescribing. For some patients, 
more recent eGFR measures may have been available 
to the prescribing GP in letters or discharge summaries 
from secondary care, while the result available to us from 
serum creatinine tests could have been measured during 
a previous acute illness. This misclassification may in part 
explain why, even in recent years, nearly 10% of patients 
appear to initiate treatment with metformin despite levels 
of renal function that should have contraindicated its use. 
We have not analysed drug intensification patterns for 
patients who did not initiate treatment with a period of 
metformin monotherapy although this is a small minority 
over recent years. We may have included a proportion of 
patients with T1DM, both those who commenced treat-
ment with insulin, and those who started on drug therapy 
but were later reclassified. However, people commencing 
insulin accounted for only 2% of drug initiations over the 
whole period so this is unlikely to have a substantial impact 
on our results. Finally, since our definition of intensifica-
tion was based on receiving a further metformin prescrip-
tion, we may have misclassified some patients as switching 
from metformin monotherapy rather than intensifying 
treatment. For example, we will have excluded some 
patients who died after intensifying treatment before 
receiving a further metformin prescription.
The prescribing trends we identified are in keeping 
with a study completed using a different source of UK 
primary care data that examined prescribing up to 2013.23 
International comparisons also show similar trends with 
falls in SU prescriptions and increases in metformin use, 
accounting for 68% of treatment initiations in Italy in 2012, 
77% in the USA in 2016, while our estimate was 84%.3 24
Our work has also highlighted an increase in prescribing 
of DPP4is for treatment intensification, similar to find-
ings in the UK and the USA.23 25 The additional period 
to 2017 covered by our analysis shows that these trends 
continued, with additional growth in SGLT2i prescribing.
Our results are also consistent with data from OpenPre-
scribing, a website that allows access to absolute numbers 
of near real-time GP prescriptions.26 OpenPrescribing 
shows increased prescribing of DPP4is and SGLT2is but 
does not distinguish prescribing at different stages of 
treatment as we present here.
In relation to prescribing for patients with reduced renal 
function, our work mirrors prescribing trends from a recent 
US study that described prescribing over time in people 
with CKD, in particular the increasing use of DPP4is.27 
Our finding that metformin continues to be prescribed 
for patients with T2DM and severely impaired renal func-
tion echoes work from France which found that for a 
cohort of people with reduced renal function prescribed 
metformin, the prescription was against contraindica-
tions in 49% of cases, and Italy where 15% of participants 
with an eGFR <30 mL/min/1.73 m2 were still prescribed 
metformin.28 29
Encouragingly, we have found that prescribing at initia-
tion of drug treatment for T2DM largely follows national 
guidelines and concordance has improved over time. We 
have highlighted that uptake of new drugs at the first 
stage of intensification has increased rapidly over recent 
years with marked regional variation suggesting factors 
outside of clinical indication may be important; guidance 
from local bodies to CCGs, drug company marketing, 
local secondary care practice and patient demand may all 
influence prescribing.30 Growing evidence that SGLT2is 
may offer long-term benefits for prevention of cardiovas-
cular disease, results not previously seen for other treat-
ments, may also have influenced prescribing, although 
guidelines have not yet been altered.20 31 Increasing use 
of patented drugs will drive up prescribing costs, an 
issue of concern as drugs for diabetes now account for 
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approximately 10% of the total cost of National Health 
Service primary care prescribing spending.32
In conclusion, our results showed marked changes in 
prescribing for T2DM since 2000 with large increases in 
prescribing of the new agents. There is substantial variation 
between regions and CCGs, despite no national guidance 
towards prescribing of specific agents. The factors under-
lying choice of drug options for the first stage of intensi-
fication are unexplained, and whether drug choice affects 
future clinical outcomes needs to be determined.
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